Nearly a year ago, Mark Cuban told Becker’s his top goals for 2025 were to sell more brand-name drugs and biosimilars and partner with additional pass-through pharmacy benefit managers.
The billionaire entrepreneur’s pharmaceutical company, aptly named Mark Cuban Cost Plus Drug Co., has steadily grown its portfolio since launching in January 2022 with about 100 medications. It now has more than 6,000 therapies.
Here are three updates on Cost Plus Drugs:
1. Potential partnership with TrumpRx
In recent weeks, Mr. Cuban said he is considering a partnership with the Trump administration’s efforts to lower drug pricing. The collaboration would link Mr. Cuban’s mail-order pharmacy through the administration’s TrumpRx.gov website, a direct-to-consumer discounted drug site set to launch in January.
2. Team Cuban Card
The Team Cuban Card — an offering that prices medications at their manufacturing cost with a 15% markup and $13 dispensing and processing fee — is now live at more than 17,000 pharmacies across the U.S.
After initially launching with 36 pharmacies in 2023, the network has rapidly expanded to include pharmacies at major grocery chains, such as Albertsons, Publix, Kroger, Food Lion and Jewel Osco.
3. New products
Cost Plus Drugs Marketplace — a company division that supplies medications to pharmacies, hospitals, surgery centers and other healthcare organizations — is expanding its injectable portfolio. The company recently added about a dozen injectable drugs to its offerings, including bupivacaine, a local anesthetic that has been in short supply for years.
Liraglutide, the generic for multiple GLP-1 medications that treat Type 2 diabetes and obesity, is another recent addition to Cost Plus Drugs’ portfolio. The company is partnering with Meitheal Pharmaceuticals, a Chicago-based pharmaceutical firm, to offer liraglutide.
In October, Mr. Cuban’s pharmaceutical company also added a brand-name flu treatment, Xofluza (baloxavir marboxil).
